No Data
No Data
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10
Express News | HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $10 Price Target
Positive Buy Rating for Zentalis Pharmaceuticals Driven by Promising Efficacy and Safety of Azenosertib in PROC Treatment
Reported Saturday, Zentalis Presented Updated DENALI Part 1b Clinical Data Demonstrating 6.3-Month MDOR And ~35% ORR With Azenosertib Monotherapy In Cyclin E1+ Platinum-Resistant Ovarian Cancer
Express News | Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer